Business
Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)
NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":" NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch (WCI) taking place from October 22-23, 2021. The group viewpoint session will cover the topic \"What I miss in itch research\" where Dr. Forbes will discuss the drug development perspective in itch, both progress, and remaining challenges. \n\n \n \n \n \n \n \n\n \nDr. Forbes, Chief Development Officer of Trevi, will participate in a virtual panel on 'What I Miss in Itch Research'\"I am looking forward to taking part in this virtual session at WCI alongside members of the itch community,\" said Bill Forbes, Pharm.D. \"Itch is an important therapeutic area for research and I am happy to continue our conversations around itch as we explore potential therapies to address the large unmet need in these patients.\" \nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.\nFounded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.\nAbout HaduvioHaduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, coug...